It has been reported that MDM2 and AMPK crosstalk is involved in the pathogenesis of PAH, and a combined intervention of MDM2 and AMPK might be a novel therapy in PAH treatment [46]. Here, MDM2 is linked to pulmonary arterial hypertension.